Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with rare neurological disorders. Founded in 2017, the company has quickly established itself in the industry, particularly in the field of sleep medicine and central nervous system disorders. With a commitment to addressing unmet medical needs, Harmony Biosciences offers unique products such as WAKIX® (pitolisant), which is designed to treat narcolepsy. This medication stands out due to its novel mechanism of action, providing patients with effective symptom management. The company has achieved significant milestones, including rapid growth and recognition for its contributions to improving patient outcomes in the neurology sector. Harmony Biosciences continues to strengthen its market position through ongoing research and development, aiming to expand its portfolio and enhance the lives of those affected by rare diseases.
DitchCarbon Score
How does Harmony Biosciences Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Harmony Biosciences Holdings, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Harmony Biosciences Holdings, Inc.'s reported carbon emissions
Harmony Biosciences Holdings, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Harmony Biosciences does not inherit any emissions data from a parent or related organization, nor does it have any commitments to the Science Based Targets initiative (SBTi) or other climate initiatives. This lack of data and commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, where sustainability and climate action are increasingly important, it is essential for companies like Harmony Biosciences to establish clear emissions reduction targets and engage in climate initiatives to align with global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Harmony Biosciences Holdings, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
